Sarah Smiley, DO
Hospitalist · Austin, TXNPI 1386672129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,250 of the $90,385 with a category attached, or 92.1%. Cipla USA Inc. accounts for 92.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $85,689 and has fallen 99.9% since, to $48 in 2025. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $2317.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$83K
- Modernatx, Inc.$3K
- AstraZeneca$2K
- Boehringer Ingelheim International GmbH$2K
- Novo Nordisk$181
- Boehringer Ingelheim$146
- plus $115 from 1 others
Across 4,434 payments — averaging $4471.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$7.4M
- GSK$3.5M
- AstraZeneca$1.3M
- Pfizer$1.1M
- Seqirus USA Inc$913K
- Vertex$861K
- plus $4.7M from 33 others
What the payments were for
- Speaking & faculty fees$83,25092%
- Travel & lodging$5,2336%
- Food & beverage$1,9022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 5 | $83,250 |
| Modernatx, Inc. | 8 | $2,928 |
| AstraZeneca | 8 | $2,216 |
| Boehringer Ingelheim International GmbH | 12 | $1,549 |
| Novo Nordisk | 2 | $181 |
| Boehringer Ingelheim | 3 | $146 |
| AbbVie | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$115
How this compares
$90,385 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 129 | $890 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $290 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $124 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Austin
- Kenechukwu EnekebeCorpus Christi$311K
- Ryan NealHouston$154K
- Mubeen CheemaSan Antonio$50K
- Ahmad BaroutHouston$44K
- Tarek HammadSan Antonio$42K
- Hendre FichardtSan Antonio$36K
- Sadie Trammell VelasquezSan Antonio$36K
- Weiyi TanDallas$30K
- Laxman KalvakuntlaHouston$30K
- Mustafa Al QaysiPearland$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.